Skip to main content
SpringerLink
Log in

New Insights and Future Advances in Cancer Diagnostics

Limitations of Conventional Tumor Markers

  • Chapter
Cancer Diagnostics

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

Tumor markers for malignant diseases can be divided into various stages, namely screening, diagnostic, monitoring and prognosis, and in the foreseeable future, preventive testing. Neither conventional serological tumor markers, spanning from carcinoembryonic antigen (CEA) (1) to prostate-specific antigen (PSA) (2), nor the genomic markers (3) reported in the past 20 yr, have risen to our expectations with regard to early diagnostic or early disease detection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gold P and Freedman SO. 1965. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122(3):3:467–481.

    Article  PubMed  CAS  Google Scholar 

  2. Ban Y, Wang MC, Chu TM. 1984. Immunologic markers and the diagnosis of prostatic cancer. Urol Clin North Am. 11(2):269–276.

    PubMed  CAS  Google Scholar 

  3. Blume-Jensen P and Hunter T. 2001. Oncogenic Kinase Signalling. Nature 411:355–365.

    Article  PubMed  CAS  Google Scholar 

  4. Wu JT. 2001. Diagnosis and management of cancer using serolgic tumor, in: Diagnosis and Management by Laboratory Method Markers. vol. 20, Henry JB, ed., S. Saunders Co., Philadelphia, pp. 1028–1042.

    Google Scholar 

  5. Landman J, Chang Y, Kavaler E, Droller MJ, Liu, BC. 1998. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology 52(3):398–402.

    Article  PubMed  CAS  Google Scholar 

  6. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D. 1979. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5(6):957–971.

    Article  PubMed  CAS  Google Scholar 

  7. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. 1981. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68(5):1331–1337.

    Article  PubMed  Google Scholar 

  8. Hanash, S. 2003. Disease Proteomics. Nature 422:226–232.

    Article  PubMed  CAS  Google Scholar 

  9. Aebersold R and Mann M. 2003. Mass spectrometry-based Proteomics. Nature 422:198–207.

    Article  PubMed  CAS  Google Scholar 

  10. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. 2002. Proteomics and bioinformatics approaches for indentification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8):1296–1304.

    PubMed  CAS  Google Scholar 

  11. Robin LS, Martinsky T, Schena M. 2003. Trends in microarray analysis. Nature Med. 9(1)1: 140–145.

    Article  Google Scholar 

  12. Balmain A. 2002. New-age tumour suppressors. Nature 417:235–237.

    Article  PubMed  CAS  Google Scholar 

  13. Couzin J. 2002. Smart weapons prove tough to design. Science 298:522–525.

    Article  PubMed  CAS  Google Scholar 

  14. Sone S, Takashima S, Li F, Yang , et al. 1998. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351(9111):1242–1245.

    Article  PubMed  CAS  Google Scholar 

  15. Lok C. 2001. Picture perfect. Nature 412:372–374.

    Article  PubMed  CAS  Google Scholar 

  16. Bel Hadj Hmida Y, Tahri N, Sellami A, Yangui N, Jlidi R, Beyrouti MI, et al. 2001. Sensitivity, specificity and prognostic value of CEA in colorectal cancer: results of a Tunisian series and literature review. Tunis. Med. 79(8–9):434–440.

    PubMed  CAS  Google Scholar 

  17. Pezzilli R, Billi P, Plate, L, Laudadio Ma, Sprovieri G. 1995. Serum CA 242 in pancreatic cancer. Comparison with CA 19–9 and CEA. Ital. J. Gastroenterol. 27(6):296–299.

    CAS  Google Scholar 

  18. Johnson PJ. 2001. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatoceller carinoma. Clin. Liver Dis. 5(1):145–159.

    Article  PubMed  CAS  Google Scholar 

  19. Aoyagi U. 2001. [Japanese]Alpha fetoprotein and I’ts fucocylation index in early Diagnostic diagnostic of Hepatocarcinomahepatocarcinoma. Nippon Rinsho. 59(6):42–348.

    Google Scholar 

  20. Takeda M, Sakuragi N, Okamoto K, et al. 2002. Preoperative serum SCC, CA125, and CA19–9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta. Obstet. Gynecol. Scand. 81(5):451–457.

    Article  PubMed  Google Scholar 

  21. Krumholtz JS, Carvalhal GF, Ramos CG, et al. 2002. Porstate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60(3):469–474.

    Article  PubMed  Google Scholar 

  22. Kokhanenko NIU, Ignashov AM, Varga EV, et al. 2001. Role of the tumor markers CA 19–9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr. Onkol. 47(3):294–297.

    PubMed  CAS  Google Scholar 

  23. Gemer O, Segal S, Kopmar A. 2001. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta. Obstet. Gynecol. Scand. 80(6): 583–585.

    Article  PubMed  CAS  Google Scholar 

  24. Tampellini M, Berruti A, Gorzegno G, et al. 2001. Independent factors predict supranormal CA 15–3 serum levels in advanced breast cancer patients at first disease relapse. Tumour Biol. 22(6):367–373.

    Article  PubMed  CAS  Google Scholar 

  25. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. 2000. Clinical significance and prognostic value of CA72–4 compared with CEA and CA19–9 in patients with gastric cancer. Dis. Markers. 16(3–4):105–110.

    Article  PubMed  CAS  Google Scholar 

  26. Yamamoto T, Ito K, Ohi M, et al. 2001. Diagnostic significance of digtal rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/mL or less. Urology 58:994–998.

    Article  PubMed  CAS  Google Scholar 

  27. D’amico AV, Whittington R, Malkowicz SB, et al. 1999. Pretreatment nomgram for prostatespecific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 17:168–172.

    PubMed  Google Scholar 

  28. Gutierrez Banos JL, Rebollo Rodrigo MH, Antolin Juarez FM, Martin Garcia, B. 2001. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int. 66(4):185–190.

    Article  PubMed  CAS  Google Scholar 

  29. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan, S, Woodman AC. 2002. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 89(4): 369–373.

    Article  PubMed  CAS  Google Scholar 

  30. Ali SM, Leitzel K, Chinchilli VM, et al. 2002. Relationship of serum HER-2/neu and serum CA 15–3 in patients with metastatic breast cancer. Clin. Chem. 48(8):1314–1320.

    PubMed  CAS  Google Scholar 

  31. Festsch PA, Simone NL, Bryant-Greewood PK, et al. 2002. Protemic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am. J. Clin. Pathol. 118(6):870–876.

    Article  Google Scholar 

  32. Petricoin EF, Ardekani AM, Hitt BA, et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572–577.

    Article  PubMed  CAS  Google Scholar 

  33. Ponder BA. 2001. Cancer genetics. Nature 411:336–341.

    Article  PubMed  CAS  Google Scholar 

  34. Evan IG and Vousden KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348.

    Article  PubMed  CAS  Google Scholar 

  35. Chakravarti A and Little P. 2003. Nature, nurture and human disease. Nature 421:412–414.

    Article  PubMed  Google Scholar 

  36. Salgia R and Skarin AT. 1998. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16(3):1207–1217.

    PubMed  CAS  Google Scholar 

  37. Rajagopalan H, Bardelli A, Lengauer C, et al. 2002. NATURE. RAF/RAS oncogenes and mismatch-repair status. Nature 418:934.

    Article  PubMed  CAS  Google Scholar 

  38. Dinxu F, Shengdao Z, Tianquan H, Yu J, Ruoging L, Zurong Y, Xuezhi W. 2002. A prospective study of detection of pancreatic carcinoma by combind plasma K-ras mutation and serum CA 19–9 analysis. Pancreas 25(4):336–341.

    Article  Google Scholar 

  39. Kovar H, Jug G, Aryee DN, et al. 1997. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15(18):2225–2232.

    Article  PubMed  CAS  Google Scholar 

  40. Zetter BZ and Banyard J. 2002. The silence of the genes. Nature 419:572–573.

    Article  PubMed  CAS  Google Scholar 

  41. Narla G, Heath KE, Reeves HL, et al. 2001. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science

    Google Scholar 

  42. Yang H, Jaffrey PD, Miller J, et al. 2002. BRCA2 Function function in DNA Binding binding and Recombination recombination from a BRCA2-DSS1-ssDNA Structurestructure. Science 297:1837–1848.

    Article  PubMed  CAS  Google Scholar 

  43. Rhee I, Backman KE, Park BH, et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552–556.

    Article  PubMed  CAS  Google Scholar 

  44. Gruber SB, Ellis NA, Rennert G, Offit K. 2002. BLM heterozygosity and the risk of colorectal cancer. Science 297:2013.

    Article  PubMed  CAS  Google Scholar 

  45. Pellegrini L, Yu DS, Lo T, et al. 2002. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420:287–290.

    Article  PubMed  CAS  Google Scholar 

  46. Penninger JM and Woodgett J. 2001. PTEN-Coupling Tumor Suppression to Stem Cells? Science 294:2116–2118.

    Article  PubMed  CAS  Google Scholar 

  47. Robert MF, Morin S, Beaulieu N, et al. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cell. Nat. Gemet. 33:61–65.

    Article  CAS  Google Scholar 

  48. Esteller M, Fraga M, Paz MF, et al. 2002. Cancer epigenetics and methylation. Science 297: 1807–1809

    Google Scholar 

  49. Varambally S, Dhanasekaran SM, Zhou M, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–628.

    Article  PubMed  CAS  Google Scholar 

  50. Dhanasekaran SM, Barrette TR, Ghosh D, et al. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826.

    Article  PubMed  CAS  Google Scholar 

  51. Mok SC, Chao J, Skates S, et al. 2001. Prostasin, a potential serum marker for ovarian cancer: indentification through microarray technology. J. Natl. Cancer Ins. 93(19):1458–1464.

    Article  CAS  Google Scholar 

  52. Shibata D, Navidi W, Salovaara R, Li Z, Aaltonen LA. 1996. Somatic microsatellite mutations as molecular tumor clocks. Nat. Med. 2(6):676–681.

    Article  PubMed  CAS  Google Scholar 

  53. Chen XQ, Stroun M, Magnenat JL, et al. 1996. Microsatllite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2(9):1033–1035.

    Article  PubMed  CAS  Google Scholar 

  54. Gebert J, Sun M, Ridder R, et al. 2000. Molecular profiling of sporadic colorectal tumors by microsatellite analysis. Int. J .Oncol. 16(1):169–179.

    PubMed  CAS  Google Scholar 

  55. Chang YC, Ho CL, Chen HH, et al. 2002. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum. Br. J. Cancer. 87(12):1449–1453.

    Article  PubMed  CAS  Google Scholar 

  56. Elemore LW, Forsythe HL, Ferreira-Gonzalez A, Garrett CT, Clark GM, Holt SE. 2002. Realtime quantitative analysis of telomerase activity in breast tumor specimens using a highly specific and sensitive fluorescent-based assay. Diagn. Mol. Pathol. 11(3):177–185.

    Article  Google Scholar 

  57. Marx J. 2002. Tackling Cancer at the telemeres. Science 295:2350–2351.

    Article  PubMed  CAS  Google Scholar 

  58. Tang SJ, Dumot JA, Wang L, et al. 2002. Telomerase activity in pancreatic endocrine tumors. Am. J. Gastroenterol. 97(4):1022–1030.

    Article  PubMed  CAS  Google Scholar 

  59. Katayama S, Shiota G, Oshimura M, Kawasaki H. 1999. Clinical usefulness of telomerase activity and telomere length in the preoperative diagnosis of gastric and colorectal cancer. J. Cancer Res. Clin. Oncol. 125(7):405–410.

    Article  PubMed  CAS  Google Scholar 

  60. Hiyama E, Gollahon L, Kataoka T, et al. 1996. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88(2):116–122.

    Article  PubMed  CAS  Google Scholar 

  61. Hess JL and Highsmith WE Jr. 2002. Telomerase detection in body fluids. Clin. Chem. 48(1):18–24.

    PubMed  CAS  Google Scholar 

  62. Bilous M. 2001. HER2 Testing Advisory Board. HER2 testing recommendations in Australia. Pathology 33(4):425–427.

    Article  PubMed  CAS  Google Scholar 

  63. Hung M, Dorsey JF, Epling-Burnette PK, et al. 2002. Inhibition of Bcr-Abl kinase activity by PD 180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21(57): 8804–8816.

    Article  Google Scholar 

  64. Marx J. 2001. Why some leukemia cells resist STI-571. Science 292:2231–2232.

    Article  PubMed  CAS  Google Scholar 

  65. Natele RB and Zaretsky SL. 2002. ZD1839 (Iressa): What’s in it for the patient? Oncologist 7(4):25–30.

    Article  Google Scholar 

  66. Herbest RS. 2002. Targeted therapy in non-small-cell lung cancer. Oncology 9(9):19–24.

    Google Scholar 

  67. Whang YE, Wu X, Suzuki H, et al. 1998. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95(9):5246–5250.

    Article  PubMed  CAS  Google Scholar 

  68. Neshat MS, Mellinghoff IK, Tran C, et al. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98(18):10,314–10,319.

    Google Scholar 

  69. Watanabe T, Katsumata N, Ando M, et al. 2002. [Japanese] Genetic testing for effective Herceptin therapy. Nippon Rinsho. 60(3):603–611.

    Google Scholar 

  70. Schubert CM. 2003. Microarray to be used as routine clinical screen. Nat. Med. 9(1):9.

    Article  PubMed  CAS  Google Scholar 

  71. Yang ZG, Sone S, Takashima S, Li F, Honda T, Maruyama Y, Hasegawa M, Kawakami S. et al. 2001. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. AJR Am. J. Roentgenol. 176(6):1399–1407.

    Article  CAS  Google Scholar 

  72. Fischer U, Vosshenrich R, Horstmann O, et al. 2002. Preoperative local MRI-staging of patients with a suspected pancreatic mass. Eur. Radiol. 12(12):296–303.

    PubMed  CAS  Google Scholar 

  73. Menon U, Talaat A, Rosenthal AN. et al. 2000. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 107(2):165–169.

    Article  PubMed  CAS  Google Scholar 

  74. Ramaswamy S, Ross K, Lander E, Golub,T. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Yasushi Kasahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Tsukada
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Scripps Clinic, La Jolla, CA, USA

    Robert M. Nakamura MD

  2. UCLA School of Medicine, Los Angeles, CA, USA

    Wayne W. Grody MD, PhD

  3. ARUP Labs, Salt Lake City, UT, USA

    James T. Wu PhD

  4. Arizona Cancer Center, Tucson, AZ, USA

    Raymond B. Nagle MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kasahara, Y., Tsukada, Y. (2004). New Insights and Future Advances in Cancer Diagnostics. In: Nakamura, R.M., Grody, W.W., Wu, J.T., Nagle, R.B. (eds) Cancer Diagnostics. Contemporary Cancer Research. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-791-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-791-8_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-399-2

  • Online ISBN: 978-1-59259-791-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation